A single particle a thousand times thinner than a human hair may not sound like the future of cancer care. Yet the same class of microscopic carriers that delivered the mRNA behind COVID-19 vaccines is now steering some of the most closely watched trials in oncology, gene editing and precision imaging. Nanoparticles have quietly moved from the laboratory bench to the pharmacy shelf, and the pace is accelerating.
Broadly, a nanoparticle is any engineered structure between roughly one and one hundred nanometres across. At that scale, materials behave differently than they do in bulk, and biology treats them differently too. A drug packaged inside the right nanoparticle can slip past barriers that would destroy it, linger in the bloodstream longer, and accumulate where it is needed rather than flooding the whole body. The U.S. National Cancer Institute keeps a running overview of how these tools are being applied across cancer nanotechnology, and the list of approved products now runs well past fifty.
Why size changes everything
The appeal of nanomedicine comes down to control. Conventional chemotherapy is famously indiscriminate: it attacks fast-dividing cells wherever it finds them, which is why hair loss, nausea and immune suppression are so common. Wrap that same drug inside a nanoparticle and you gain a steering wheel. Engineers can tune the particle’s surface, charge and size so that it circulates quietly until it reaches a tumour, then releases its payload close to the target.
Solid tumours also help by accident. Their blood vessels tend to be leaky and their drainage poor, so particles of the right dimensions tend to seep in and stay put, a quirk researchers call the enhanced permeability and retention effect. Add a targeting molecule to the surface, and the particle can seek out receptors that appear on cancer cells more than on healthy ones. The result, in principle, is more drug where the disease is and less everywhere else.
From pandemic vaccines to personalised cancer shots
No nanoparticle has had a bigger public moment than the lipid nanoparticle, or LNP. These fatty spheres were the unsung workhorse of the mRNA vaccines rolled out during the pandemic, shielding a fragile strand of genetic instructions long enough to reach human cells. That success turned LNPs into one of the hottest platforms in drug development.
The most striking application now in trials is the personalised cancer vaccine. Researchers sequence a patient’s tumour, identify the mutations that make it unique, and encode those targets into mRNA carried by lipid nanoparticles. Injected back into the patient, the vaccine trains the immune system to hunt cells bearing those specific flags. Melanoma has produced the most encouraging early data, and studies are extending the approach to lung and other solid tumours. It is a strategy that would have been science fiction a decade ago, built on infrastructure the pandemic forced the world to perfect.
Targeting tumours while sparing healthy tissue
Long before mRNA, nanoparticles were already reshaping chemotherapy. Doxil, a liposomal form of the drug doxorubicin, became the first nanomedicine cleared by regulators back in the 1990s, and it is still in use because the packaging blunts the drug’s damage to the heart. A whole family of liposomal cancer drugs followed, each trying to widen the gap between effect and side effect.
| Nanomedicine | Encapsulated drug | Main use |
|---|---|---|
| Doxil | Doxorubicin | Ovarian cancer, myeloma |
| Onivyde | Irinotecan | Pancreatic cancer |
| Marqibo | Vincristine | Acute lymphoblastic leukaemia |
| DaunoXome | Daunorubicin | Kaposi sarcoma |
| Myocet | Doxorubicin | Metastatic breast cancer |
The commercial stakes match the clinical ones. The market for liposomal cancer therapeutics alone was valued at roughly 3.7 billion US dollars in 2021 and is expected to approach 7 billion by 2027, according to industry analysts. That growth is one reason the field keeps attracting both pharmaceutical giants and a long tail of biotech start-ups. For a wider view of how these tools fit into the broader field, our overview of nanotechnology in medicine traces the same story across diagnostics and regenerative therapies.
Gene editing, imaging and the next frontier
Delivery is the quiet bottleneck of gene therapy, and nanoparticles are increasingly the answer. In vivo CRISPR treatments, which edit genes inside the body rather than in a dish, rely on lipid nanoparticles to ferry the editing machinery to the liver, where it can correct the instructions behind inherited disorders. Early programmes targeting rare metabolic and blood conditions have shown that a carefully engineered particle can carry a gene-editing tool to exactly the tissue that needs it.
Metals bring their own tricks. Gold nanoparticles can be tuned to absorb light and heat, opening the door to therapies that cook tumours from within or light them up for surgeons. Iron-oxide particles respond to magnetic fields, which makes them useful both as contrast agents in imaging and as beacons that mark the fuzzy border of a tumour during an operation. Researchers are even testing particles designed to slip past the blood-brain barrier, one of the most stubborn obstacles in treating brain cancer. The same appetite for precision is driving neighbouring fields, from the brain-computer interfaces now entering human trials to the enormous computing clusters that speed up the molecular design behind these particles.
The four particle families doing the work
The phrase covers several unrelated chemistries, and the differences decide what a particle can carry and where it ends up. Lipid nanoparticles are fatty spheres built around an ionizable lipid that is neutral in the bloodstream and becomes positively charged inside the acidic compartment of a cell, which is the trick that lets messenger RNA escape into the cytoplasm. Liposomes, the oldest family, are hollow lipid bubbles that carry small-molecule drugs. Polymeric particles trade some loading efficiency for control over how slowly a drug is released. Inorganic particles, mostly gold and iron oxide, are less about delivery and more about being seen or heated on command.
| Particle family | Typical cargo | Approved example | What it is used for |
|---|---|---|---|
| Lipid nanoparticle | mRNA, siRNA | Comirnaty, Spikevax, Onpattro | Vaccines and gene silencing |
| Liposome | Small-molecule chemotherapy | Doxil, Onivyde | Reducing cardiac and systemic toxicity |
| Protein-bound particle | Poorly soluble chemotherapy | Abraxane | Delivering paclitaxel without solvents |
| Inorganic (iron oxide, gold) | None, the particle is the agent | Feraheme | Imaging contrast, iron replacement, heating |
That table is the honest answer to the question of whether any of this is real yet. Several of these have been on pharmacy shelves for years, and the mRNA vaccines of 2020 and 2021 were not a breakthrough in nanoparticle science so much as the moment a thirty-year-old delivery technology finally met a cargo worth the effort.
Canada is further up this supply chain than most people realise
The ionizable lipid chemistry behind the mRNA vaccines traces back in large part to work done in British Columbia, and the country still holds real ground in the manufacturing layer. Precision NanoSystems, founded in Vancouver, built the microfluidic mixing platforms used by laboratories worldwide to assemble lipid nanoparticles reproducibly. In February 2021 the federal Strategic Innovation Fund committed 25.1 million dollars toward a Vancouver biomanufacturing centre for RNA lipid nanoparticle vaccines and genetic medicines. Danaher acquired the company in June 2021 and confirmed the Vancouver facility would proceed.
That matters for a practical reason. The hardest part of a nanoparticle medicine is not designing it but making the same particle twice, at scale, to a regulator’s satisfaction. Domestic capacity in that specific step is what separates a country that can respond to the next outbreak from one that waits in line.
A market growing as fast as the science
Put the pieces together and nanomedicine has become one of the fastest-expanding corners of healthcare. Analyst estimates for the total market in 2025 range widely, from around 230 billion to well over 370 billion US dollars depending on how the category is defined, but they agree on direction: most forecasts see the sector more than doubling over the next decade, with annual growth rates in the low-to-mid teens. Gene-therapy delivery, powered largely by lipid nanoparticles, is expanding faster still.
The obstacles are real. Manufacturing nanoparticles at scale, with the same quality batch after batch, remains difficult and expensive. Regulators are still refining how to evaluate products that behave unlike ordinary drugs. And questions about long-term safety and how the body clears these materials will only grow as more particles enter clinical use. None of that has slowed the momentum. If the past five years belonged to the vaccine, the next five may belong to the far broader promise of medicine delivered one nanoparticle at a time.
Frequently asked questions
What exactly is a nanoparticle in medicine?
It is an engineered particle, usually between one and one hundred nanometres wide, built to carry a drug, a piece of genetic material or an imaging agent to a specific place in the body. The particle protects its cargo and helps control where and when it is released.
Are nanoparticle medicines already approved?
Yes. More than fifty nanomedicines have been approved by the U.S. FDA, covering cancer, infectious disease and other conditions. Familiar examples include liposomal chemotherapy drugs and the lipid nanoparticles used in mRNA vaccines.
How do nanoparticles reduce side effects?
By keeping a drug packaged until it reaches its target, nanoparticles limit how much of it reaches healthy tissue. That can reduce the collateral damage that makes treatments such as chemotherapy so hard to tolerate.
What is the biggest challenge ahead?
Manufacturing consistency, cost and long-term safety are the main hurdles. Making identical particles at industrial scale is technically demanding, and researchers are still studying how the body handles them over time.
Is there a difference between nanoparticles in medicine and nanotechnology in medicine?
Yes. Nanoparticles are one class of tool. Nanotechnology in medicine is the wider field, taking in nanoscale sensors, surface coatings for implants, scaffolds for tissue engineering and diagnostic devices that never involve an injected particle at all. Our broader survey of nanotechnology in medicine covers those other branches.
How small is a medical nanoparticle?
Most therapeutic particles fall between 50 and 200 nanometres across. A red blood cell is about 7,000 nanometres wide, so several dozen particles would sit across one. Below roughly 10 nanometres the kidneys clear particles almost immediately; above about 200 nanometres the liver and spleen filter them out. The useful window is narrow, and hitting it is a manufacturing problem as much as a design one.
Are nanoparticle medicines approved in Canada?
Yes. Health Canada has authorised liposomal chemotherapy agents, iron oxide preparations and the mRNA vaccines, all of which are nanoparticle products. There is no separate regulatory category for them. Each is assessed as a drug, with additional scrutiny of particle size distribution and batch-to-batch consistency.
Do nanoparticles stay in the body?
Lipid nanoparticles break down within days, their components metabolised like other lipids. Inorganic particles are the open question. Iron oxide is processed through normal iron handling pathways, but gold and other metals clear slowly and long-term data is still being gathered, which is one reason approvals in that category have been cautious.
